Page last updated: 2024-09-02

oxymatrine and Dyslipidemias

oxymatrine has been researched along with Dyslipidemias in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hu, ZJ; Shi, L; Shi, LJ; Song, GY; Wang, C; Zhang, DH; Zhang, HF	1

Other Studies

1 other study(ies) available for oxymatrine and Dyslipidemias

Article	Year
Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated recep European journal of pharmacology, 2013, Aug-15, Volume: 714, Issue:1-3 Topics: Alkaloids; Animals; Body Weight; Diet; Dose-Response Relationship, Drug; Dyslipidemias; Energy Intake; Fatty Acids; Fatty Liver; Fructose; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; PPAR alpha; Quinolizines; Rats; Rats, Wistar; RNA, Messenger; Signal Transduction; Sterol Regulatory Element Binding Protein 1	2013

Article

Year

Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated recep

European journal of pharmacology, 2013, Aug-15, Volume: 714, Issue:1-3

Topics: Alkaloids; Animals; Body Weight; Diet; Dose-Response Relationship, Drug; Dyslipidemias; Energy Intake; Fatty Acids; Fatty Liver; Fructose; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; PPAR alpha; Quinolizines; Rats; Rats, Wistar; RNA, Messenger; Signal Transduction; Sterol Regulatory Element Binding Protein 1

2013